22Nov/18
Research and Development of Blinatumomab in B Cell Malignant Tumor
Blinatumomab is a CD19/CD3 bispecific antibody that is the first bispecific T cell engager (BiTE) and the first CD19-specific antibody approved by the U.S. Food and Drug Administration (FDA). As an immunotherapyRead More…